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Abstract
The BRCA1/2 genes account for a significant portion of hereditary breast and ovarian cancers and they are
especially prevalent in the Ashkenazi Jewish population. Women who have a mutation can prevent breast and
ovarian cancer with surgical intervention. We describe an Ashkenazi Jewish patient who illustrates that current
testing criteria are too restrictive, particularly for this population of patients. The patient’s sister was diagnosed with
breast cancer at age 33; however, she was not a mutation carrier. Based on practice guidelines, the patient was not
recommended genetic testing. She subsequently underwent direct-to-consumer (DTC) testing and discovered that
she was a mutation carrier. This case demonstrates the need for clinicians to be aware of the higher prevalence of
BRCA mutations in the Ashkenazi population. It also exemplifies the need to involve medical professionals,
including genetic counselors, in the dissemination of DNA test results.
The BRCA1/2 genes account for a significant portion of
hereditary breast and ovarian cancers. BRCA1 mutation
carriers have a 47 to 66% chance of developing breast
cancer and a 35 to 46% chance of developing ovarian
cancer by the age of 70 [1]. BRCA2 mutation carriers
have a 40 to 57% chance of developing breast cancer
and a 13 to 23% chance of developing ovarian cancer by
the age of 70 [1]. These numbers are striking as com-
pared to a 12.5% lifetime risk of breast cancer and a
1.5% lifetime risk of ovarian cancer in the general
population.
One out of forty individuals of Ashkenazi Jewish heri-
tage test positive for one of three “founder” mutations:
187delAG and 5385insC in BRCA1 and 6174delT in
BRCA2 [2]. This is at least ten times higher than the fre-
quency of mutations in the general population. The
importance of identifying carriers is to improve their survi-
val. Women who have a mutation can prevent breast and
ovarian cancer with surgical interventions such as bilateral
prophylactic mastectomy and/or bilateral prophylactic sal-
pingo-oophorectomy. For those who choose increased sur-
veillance, the aim is to improve survival through earlier
discovery and treatment when the cancer is detected.
Since eighty-five percent of carriers will develop a breast
cancer, in addition to surgical procedures they will usually
r e q u i r es y s t e m i ct h e r a p y ,w hich involves significant
expense and side effects, and face the known mortality of
the disease. There is no adequate or comparable surveil-
lance for ovarian cancer.
We recently encountered a healthy 30-year-old Ashke-
nazi Jewish female who did not have a personal history of
breast or ovarian cancer. Her family history included a sis-
ter who was diagnosed with breast cancer at age 33 [see
Figure 1]. The affected sister underwent targeted and com-
plete sequencing for BRCA1 and BRCA2 and no mutation
was detected. In adherence with current practice guide-
lines, our patient had been advised that she did not need
to pursue genetic testing. This was because the ideal can-
didate in the family – her sister with breast cancer – had
already undergone testing and was not a carrier.
On her own, the patient sent a saliva sample to a
direct-to-consumer (DTC) online genetic testing com-
pany and discovered that she was a carrier of one of the
three Ashkenazi Jewish founder mutations, BRCA1
5385insC. To confirm this result, we submitted a blood
sample to Myriad Genetic Laboratory. Since the preva-
lence of these mutations is high in the Ashkenazi Jewish
population, it is not implausible to find a healthy sibling
carries a founder mutation, even when the affected sib-
ling is negative. It is also not unusual to detect two differ-
ent BRCA founder mutations in the same family, often
because of masking of transmission through male
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all Ashkenazi Jewish candidates for the three founder
mutations, even if a mutation has been previously identi-
fied in the family.
There has been criticism of DTC marketing; however,
this case of serendipitous discovery illustrates a situation
where DTC testing was extremely useful. While our
patient felt that embarking upon genetic testing over the
internet was not ideal, she was grateful to learn about her
carrier status. The patient sought genetic counseling and
elected to undergo bilateral mastectomies. She has signif-
icantly reduced her risk of developing breast cancer, and
she also plans to pursue bilateral salpingo-oophorectomy
upon completion of childbearing.
Since the three founder mutations account for approxi-
mately 96% of mutations in the Ashkenazi population, all
such women diagnosed with breast or ovarian cancer are
eligible for targeted testing under NCCN guidelines [3].
The founder mutation panel costs $575 through Myriad,
versus $3340 for complete gene sequencing. These
women need not have any additional family history of
cancers. If, however, they are not found to carry a muta-
tion, insurance coverage for other unaffected family
members is often limited.
In a recent article by Metcalfe et al., over 2000 Ashke-
nazi Jewish women were tested for the three founder
mutations [4]. Among the mutation carriers, the mean
estimate of carrying a BRCA mutation was 3.9%. Only
45% of the carriers, however, met family history criteria
for testing. Based on these findings, the authors proposed
that general population screening in Ashkenazi Jewish
women should be considered. We agree that this would be
ideal. Certainly, the criteria for testing should not be as
restrictive as currently accepted guidelines. Rubinstein et
al. report that over half of unaffected Ashkenazi Jewish
BRCA1/2 carriers cannot be identified by relying solely on
family history [5]. The authors further conclude that
population screening for the founder mutations in the
Ashkenazi population is cost-effective. While the financial
analysis was based on ovarian cancer outcomes alone, the
dollars saved and quality-adjusted life years gained makes
the implementation of such a program worthy of further
consideration.
This case demonstrates the need for clinicians to be
aware of the higher prevalence of BRCA mutations in the
Ashkenazi population. The current guidelines do not iden-
tify women who may be carriers, to their detriment. Breast
cancer is common enough in the Ashkenazi population
that random cancers may develop and it should not be
assumed that unaffected siblings cannot be carriers. This
case also exemplifies the need to involve medical profes-
sionals, including genetic counselors, in the dissemination
of DNA test results. This patient received notification of
her positive carrier status via email format buried amongst
other less medically relevant information.
Physicians have learned to follow guidelines in recom-
mending mammography screening for women starting
at the age of forty, and earlier for those with a family
Figure 1 Patient Pedigree.
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porated in a similar manner and earlier as the family
history dictates. As we approach the era of personalized
genomic medicine [6], the role of clinicians will expand
to include interpretation of such genetically important
findings.
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